Aptorum Group Limited (NASDAQ:APM – Get Free Report)’s stock price dropped 4.6% on Thursday . The company traded as low as $0.60 and last traded at $0.6680. 167,078 shares were traded during trading, an increase of 188% from the average daily volume of 57,956 shares. The stock had previously closed at $0.70.
Analysts Set New Price Targets
Separately, Weiss Ratings raised shares of Aptorum Group from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, July 16th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company presently has an average rating of “Sell”.
Read Our Latest Stock Analysis on Aptorum Group
Aptorum Group Stock Performance
About Aptorum Group
Aptorum Group Ltd. (NASDAQ: APM) is a global biopharmaceutical company incorporated under the laws of the Cayman Islands and headquartered in Hong Kong. Since its Nasdaq listing in 2018, the company has focused on the discovery, development and commercialization of novel therapeutics and diagnostic products. Aptorum’s research efforts are aimed at addressing unmet medical needs across oncology, metabolic disorders, infectious diseases and neurological conditions.
The company’s diversified pipeline includes both small-molecule and biologic drug candidates, as well as companion diagnostic tools.
Recommended Stories
- Five stocks we like better than Aptorum Group
- Sandisk Just Delivered a Blowout Quarter—Here’s Why the Stock Is Falling
- 4 Oil and Gas ETF Plays as Prices Stay Sky-High
- What Tesla Stands to Lose If It Walks Away From China
- Disney Sets Up for a Magical Year in 2027
Receive News & Ratings for Aptorum Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptorum Group and related companies with MarketBeat.com's FREE daily email newsletter.
